Dual Antiplatelet Therapy (DAPT) in Patients With Baseline Thrombocytopenia
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- Incidence of bleeding
研究概览
简要总结
The use of clopidogrel as part of DAPT will be associated with lower bleeding rates compared to ticagrelor in patients with chronic thrombocytopenia requiring Percutaneous intervention (PCI )with Drug Eluting Stent (DES) or Bare Metal Stint(BMS).
详细描述
Patients with thrombocytopenia are at an increased risk of both bleeding and ischemic events following PCI; however, there is a paucity of data on how to optimally manage these risks. Data indicates that ticagrelor is associated with reduced ischemic outcomes with an accompanying increased risk of bleed in the broader population. This study will assess P2Y12 agent selection in patients with chronic thrombocytopenia to determine if one better balances risks of ischemic and bleeding events following coronary intervention
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years
- •PCI with either DES or BMS during study time period (April 1, 2018 through July 1 2021)
- •Thrombocytopenia defined as platelet count <100 x103 /µL on at least one occasion prior to PCI
- •At least one dose of DAPT post-PCI with aspirin and either clopidogrel or ticagrelor
排除标准
- •Death within 48 hours post-PCI
- •DAPT prior to cardiac catheterization
结局指标
主要结局
Incidence of bleeding
时间窗: 1 year
To evaluate the difference in bleeding rates in patients with chronic thrombocytopenia maintained on DAPT with clopidogrel compared to patients maintained on DAPT with ticagrelor.
次要结局
- Incidence of ischemic events(1 year)
- All-cause mortality(1 year)
- Duration of DAPT(1 year)